The journal of sexual medicine · 2026
The prevalence and risk factors of female sexual dysfunction in breast cancer survivors: a systematic review and meta-analysis.
СтатьяСистематический обзорМетаанализНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Liu Yuyan, Sun Dan, Wen Yuhang, Zhao Hui, Long Yu, Yu Qiongge, Jia Qiufeng, Yu Yufeng
Аннотация
INTRODUCTION: Female sexual dysfunction (FSD) is a common issue, but currently only a few studies have evaluated the problem in breast cancer survivors.
OBJECTIVES: We aim to systematically evaluate the prevalence and risk factors of FSD among breast cancer survivors globally.
METHODS: We searched PubMed, Embase, Web of Science, Cochrane Library, Scopus, CNKI, SinoMed, WanFang, and VIP databases from January 1, 2014 to October 10, 2025, to identify studies on the prevalence and risk factors of FSD in breast cancer survivors. Two researchers independently screened the literature, extracted data, and assessed the risk of bias. Finally, a meta-analysis was conducted using Stata 17.
RESULTS: A total of 36 studies were included, involving 9749 breast cancer survivors. The meta-analysis showed that the pooled prevalence of FSD among global breast cancer survivors was 70% (95% CI, [64%-76%]), and the prevalence of sexual distress was 57% (95% CI, [29%-86%]). There were significant differences in the prevalence of FSD among different educational levels, economic development levels, pathological stages, surgical methods, and first post-operative sexual intercourse time. Mastectomy, adjuvant therapies, dissatisfaction with body image, and lack of sexual counseling were all risk factors for FSD in breast cancer survivors.
CONCLUSION: Female sexual dysfunction is a common issue among breast cancer survivors, disease-related factors and the lack of sexual counseling are significantly associated with FSD, and sexual health assessment should be incorporated into the routine diagnosis and treatment of breast cancer in the future.
OBJECTIVES: We aim to systematically evaluate the prevalence and risk factors of FSD among breast cancer survivors globally.
METHODS: We searched PubMed, Embase, Web of Science, Cochrane Library, Scopus, CNKI, SinoMed, WanFang, and VIP databases from January 1, 2014 to October 10, 2025, to identify studies on the prevalence and risk factors of FSD in breast cancer survivors. Two researchers independently screened the literature, extracted data, and assessed the risk of bias. Finally, a meta-analysis was conducted using Stata 17.
RESULTS: A total of 36 studies were included, involving 9749 breast cancer survivors. The meta-analysis showed that the pooled prevalence of FSD among global breast cancer survivors was 70% (95% CI, [64%-76%]), and the prevalence of sexual distress was 57% (95% CI, [29%-86%]). There were significant differences in the prevalence of FSD among different educational levels, economic development levels, pathological stages, surgical methods, and first post-operative sexual intercourse time. Mastectomy, adjuvant therapies, dissatisfaction with body image, and lack of sexual counseling were all risk factors for FSD in breast cancer survivors.
CONCLUSION: Female sexual dysfunction is a common issue among breast cancer survivors, disease-related factors and the lack of sexual counseling are significantly associated with FSD, and sexual health assessment should be incorporated into the routine diagnosis and treatment of breast cancer in the future.